Blog

NCCN updates guidelines, favoring DPYD testing for colon, anal, rectal, and small bowel cancers – Precision Medicine

oregoncancer.com

Apr 3, 2025, 12:42

NCCN updates guidelines, favoring DPYD testing for colon, anal, rectal, and small bowel cancers – Precision Medicine

Precision Medicine shared a post on LinkedIn:

“The National Comprehensive Cancer Network (NCCN) has updated its guidelines for colon, anal, rectal, and small bowel cancer treatment, taking a more favorable stance on DPYD pharmacogenetic testing.

What does this mean?

Doctors are now advised to discuss DPYD testing with patients to assess their risk of severe or life-threatening toxicities from fluoropyrimidine-based chemotherapies.
This testing can help identify patients who may require adjusted chemotherapy dosing to minimize risks.

Why is this important?

DPYD genetic variants can affect how patients metabolize certain chemotherapies, increasing the risk of toxicities.
By identifying these variants, healthcare providers can take steps to personalize treatment and improve patient outcomes.”

Radu Serescu, Oncologist at Amethyst Radiotherapy Romania, shared this post, adding:

“Implemented since 2021, a small percentage may exhibit toxicity to Capecitabine or 5-FU through deficient metabolism given by DPD. Testing for Amethyst! Health comes first, so I’d better inform you!”

More posts featuring Precision Medicine.

Anal Cancer cancer Colon cancer DPYD DPYD pharmacogenetic testing National Comprehensive Cancer Network NCCN OncoDaily Oncology Precision Medicine Radu Serescu rectal cancer small bowel cancer

Where to Study to Become ASCO President: 2025 Institutional Rankings

Yelak Biru: UK grants first approval for Blenrep in multiple myeloma

Eric Abidal and Liver Cancer: How He Returned to Football After Overcoming Illness

Dr. Don Dizon and Dr. Nathan Pennell Reflect on the Evolution of the ASCO Educational Book

April is Head and Neck Cancer Awareness Month